Improving Antithrombotic Management in Patients With Atrial Fibrillation: Current Status and Perspectives

 

 Permissions and Reprints

ABSTRACT

Despite overwhelming evidence of the benefits of risk-adjusted oral anticoagulation on stroke reduction in patients with atrial fibrillation (AF), there is still considerable undertreatment. A multidisciplinary expert group was formed to discuss issues surrounding anticoagulant treatment of patients with AF to try and achieve consensus on various aspects of the implementation of guidelines on oral anticoagulation therapy in AF. Panel members were cardiologists, hematologists, and laboratory and primary care physicians with specific expertise from Europe and the United States. One of the most important conclusions of the meeting was to enhance guideline adherence by better communication of the data showing that the benefits of stroke reduction outweigh the risk of bleeding associated with treatment with vitamin K antagonists. Management of oral anticoagulation therapy by dedicated centers, such as anticoagulation clinics, or by patient self-management may improve the quality of anticoagulation and facilitate the management of these patients and thereby further facilitate optimal antithrombotic management in patients with AF.

REFERENCES

• 1 Fuster V, Rydén L E, Cannom D S American College of Cardiology/American Heart Association Task Force on Practice Guidelines et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.  Circulation. 2006;  114(7) e257-e354
  CrossrefPubMedGoogle Scholar
• 2 Hylek E M, Go A S, Chang Y et al.. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.  N Engl J Med. 2003;  349(11) 1019-1026
  CrossrefPubMedGoogle Scholar
• 3 Go A S, Hylek E M, Phillips K A et al.. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.  JAMA. 2001;  285(18) 2370-2375
  CrossrefPubMedGoogle Scholar
• 4 Kannel W B, Benjamin E J. Status of the epidemiology of atrial fibrillation.  Med Clin North Am. 2008;  92(1) 17-40 ix
  CrossrefPubMedGoogle Scholar
• 5 Feinberg W M, Blackshear J L, Laupacis A, Kronmal R, Hart R G. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications.  Arch Intern Med. 1995;  155(5) 469-473
  CrossrefPubMedGoogle Scholar
• 6 Miyasaka Y, Barnes M E, Gersh B J et al.. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence.  Circulation. 2006;  114(2) 119-125
  CrossrefPubMedGoogle Scholar
• 7 WHO Monica Study .Decision resources. http://Available at: www.klt.Fi/monica
  Google Scholar
• 8 Statistisches Bundesamt . 2007;  http://Available at: www.destatis.de
  PubMed
• 9 Davies M, Hobbs F, Davis R et al.. Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study.  Lancet. 2001;  358(9280) 439-444
  CrossrefPubMedGoogle Scholar
• 10 Heeringa J, van der Kuip D A, Hofman A et al.. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study.  Eur Heart J. 2006;  27(8) 949-953
  CrossrefPubMedGoogle Scholar
• 11 Di Carlo A, Baldereschi M, Gandolfo C ILSA Working Group et al. Stroke in an elderly population: incidence and impact on survival and daily function.  Cerebrovasc Dis. 2003;  16(2) 141-150
  CrossrefPubMedGoogle Scholar
• 12 Filippi A, Bettoncelli G, Zaninelli A. Detected atrial fibrillation in north Italy: rates, calculated stroke risk and proportion of patients receiving thrombo-prophylaxis.  Fam Pract. 2000;  17(4) 337-339
  CrossrefPubMedGoogle Scholar
• 13 National Center of Epidemiology Surveillance and Health Promotion, Italian Institute of Health. . The Italian Cardiovascular Epidemiological Observatory.  Ital Heart J. 2004;  5(suppl 3) 29S-92S
  PubMedGoogle Scholar
• 14 Nieuwlaat R, Capucci A, Camm A J European Heart Survey Investigators et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation.  Eur Heart J. 2005;  26(22) 2422-2434
  CrossrefPubMedGoogle Scholar
• 15 Friberg J, Scharling H, Gadsbøll N, Truelsen T, Jensen G B. Copenhagen City Heart Study . Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study).  Am J Cardiol. 2004;  94(7) 889-894
  CrossrefPubMedGoogle Scholar
• 16 Wolf P A, Abbott R D, Kannel W B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.  Stroke. 1991;  22(8) 983-988
  CrossrefPubMedGoogle Scholar
• 17 Page R L, Tilsch T W, Connolly S J Azimilide Supraventricular Arrhythmia Program (ASAP) Investigators et al. Asymptomatic or “silent” atrial fibrillation: frequency in untreated patients and patients receiving azimilide.  Circulation. 2003;  107(8) 1141-1145
  CrossrefPubMedGoogle Scholar
• 18 Kerr C, Boone J, Connolly S et al.. Follow-up of atrial fibrillation: the initial experience of the Canadian Registry of Atrial Fibrillation.  Eur Heart J. 1996;  17(suppl C) 48-51
  PubMedGoogle Scholar
• 19 American Heart Association .Heart disease and stroke statistics. Update. 2008. http://Available at: www.americanheart.org/presenter.jhtml
  Google Scholar
• 20 Dulli D A, Stanko H, Levine R L. Atrial fibrillation is associated with severe acute ischemic stroke.  Neuroepidemiology. 2003;  22(2) 118-123
  CrossrefPubMedGoogle Scholar
• 21 Lin H J, Wolf P A, Kelly-Hayes M et al.. Stroke severity in atrial fibrillation. The Framingham Study.  Stroke. 1996;  27(10) 1760-1764
  CrossrefPubMedGoogle Scholar
• 22 Kannel W B, Abbott R D, Savage D D, McNamara P M. Epidemiologic features of chronic atrial fibrillation: the Framingham study.  N Engl J Med. 1982;  306(17) 1018-1022
  CrossrefPubMedGoogle Scholar
• 23 Vidaillet H, Granada J F, Chyou P H et al.. A population-based study of mortality among patients with atrial fibrillation or flutter.  Am J Med. 2002;  113(5) 365-370
  CrossrefPubMedGoogle Scholar
• 24 Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.  Chest. 2004;  126(3, suppl) 204S-233S
  CrossrefPubMedGoogle Scholar
• 25 White H D, Gruber M, Feyzi J et al.. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V.  Arch Intern Med. 2007;  167(3) 239-245
  CrossrefPubMedGoogle Scholar
• 26 Go A S, Hylek E M, Chang Y et al.. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?.  JAMA. 2003;  290(20) 2685-2692
  CrossrefPubMedGoogle Scholar
• 27 Hart R G, Benavente O, McBride R, Pearce L A. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis.  Ann Intern Med. 1999;  131(7) 492-501
  PubMedGoogle Scholar
• 28 Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.  Arch Intern Med. 1994;  154(13) 1449-1457
  CrossrefPubMedGoogle Scholar
• 29 Hart R G, Pearce L A, Aguilar M I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.  Ann Intern Med. 2007;  146(12) 857-867
  CrossrefPubMedGoogle Scholar
• 30 Aguilar M I, Hart R, Pearce L A. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks.  Cochrane Database Syst Rev. 2007;  (3) CD006186
  PubMedGoogle Scholar
• 31 van Walraven C, Hart R G, Singer D E et al.. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis.  JAMA. 2002;  288(19) 2441-2448
  CrossrefPubMedGoogle Scholar
• 32 Petersen P, Boysen G, Godtfredsen J, Andersen E D, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study.  Lancet. 1989;  1(8631) 175-179
  PubMedGoogle Scholar
• 33 Gulløv A L, Koefoed B G, Petersen P et al.. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study.  Arch Intern Med. 1998;  158(14) 1513-1521
  CrossrefPubMedGoogle Scholar
• 34 Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study.  Lancet. 1994;  343(8899) 687-691
  PubMedGoogle Scholar
• 35 EAFT (European Atrial Fibrillation Trial) Study Group . Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke.  Lancet. 1993;  342(8882) 1255-1262
  PubMedGoogle Scholar
• 36 Rash A, Downes T, Portner R, Yeo W W, Morgan N, Channer K S. A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO).  Age Ageing. 2007;  36(2) 151-156
  CrossrefPubMedGoogle Scholar
• 37 Healey J S, Hart R G, Pogue J et al.. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W).  Stroke. 2008;  39(5) 1482-1486
  CrossrefPubMedGoogle Scholar
• 38 Hu D Y, Zhang H P, Sun Y H, Jiang L Q. Antithrombotic Therapy in Atrial Fibrillation Study Group . The randomized study of efficiency and safety of antithrombotic therapy in nonvalvular atrial fibrillation: warfarin compared with aspirin [in Chinese].  Zhonghua Xin Xue Guan Bing Za Zhi. 2006;  34(4) 295-298
  PubMedGoogle Scholar
• 39 Hellemons B S, Langenberg M, Lodder J et al.. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin.  BMJ. 1999;  319(7215) 958-964
  PubMedGoogle Scholar
• 40 Pérez-Gómez F, Alegría E, Berjón J NASPEAF Investigators et al. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study.  J Am Coll Cardiol. 2004;  44(8) 1557-1566
  CrossrefPubMedGoogle Scholar
• 41 Morocutti C, Amabile G, Fattapposta F et al.. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale). Investigators.  Stroke. 1997;  28 1015-1021
  PubMedGoogle Scholar
• 42 Mant J, Hobbs F D, Fletcher K BAFTA investigators et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial.  Lancet. 2007;  370(9586) 493-503
  CrossrefPubMedGoogle Scholar
• 43 Atwood J E, Albers G W. Anticoagulation and atrial fibrillation.  Herz. 1993;  18(1) 27-38
  PubMedGoogle Scholar
• 44 Fang M C, Go A S, Chang Y et al.. Death and disability from warfarin-associated intracranial and extracranial hemorrhages.  Am J Med. 2007;  120(8) 700-705
  CrossrefPubMedGoogle Scholar
• 45 Levi M, Hovingh G K, Cannegieter S C, Vermeulen M, Büller H R, Rosendaal F R. Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based.  Blood. 2008;  111(9) 4471-4476
  CrossrefPubMedGoogle Scholar
• 46 van Walraven C, Hart R G, Singer D E, Koudstaal P J, Connolly S. Oral anticoagulants vs. aspirin for stroke prevention in patients with non-valvular atrial fibrillation: the verdict is in.  Card Electrophysiol Rev. 2003;  7(4) 374-378
  CrossrefPubMedGoogle Scholar
• 47 Hylek E M, Evans-Molina C, Shea C, Henault L E, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation.  Circulation. 2007;  115(21) 2689-2696
  CrossrefPubMedGoogle Scholar
• 48 National Collaborating Centre for Chronic Conditions .Atrial Fibrillation: National Clinical Guideline for Management in Primary and Secondary Care. London, United Kingdom; Royal College of Physicians 2006
  Google Scholar
• 49 Albers G W, Dalen J E, Laupacis A, Manning W J, Petersen P, Singer D E. Antithrombotic therapy in atrial fibrillation.  Chest. 2001;  119(1, suppl) 194S-206S
  CrossrefPubMedGoogle Scholar
• 50 Fumeaux T, Cornuz J, Polikar R et al.. Guidelines for the clinical management of atrial fibrillation: a practical perspective.  Swiss Med Wkly. 2004;  134(17–18) 235-247
  PubMedGoogle Scholar
• 51 Stroke Risk in Atrial Fibrillation Working Group . Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation.  Stroke. 2008;  39(6) 1901-1910
  CrossrefPubMedGoogle Scholar
• 52 Hart R G, Halperin J L. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention.  Ann Intern Med. 1999;  131(9) 688-695
  PubMedGoogle Scholar
• 53 Gage B F, Waterman A D, Shannon W, Boechler M, Rich M W, Radford M J. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.  JAMA. 2001;  285(22) 2864-2870
  CrossrefPubMedGoogle Scholar
• 54 Hylek E M, Singer D E. Risk factors for intracranial hemorrhage in outpatients taking warfarin.  Ann Intern Med. 1994;  120(11) 897-902
  CrossrefPubMedGoogle Scholar
• 55 Fihn S D, Callahan C M, Martin D C, McDonell M B, Henikoff J G, White R H. The National Consortium of Anticoagulation Clinics . The risk for and severity of bleeding complications in elderly patients treated with warfarin.  Ann Intern Med. 1996;  124(11) 970-979
  CrossrefPubMedGoogle Scholar
• 56 Hart R G, Boop B S, Anderson D C. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses.  Stroke. 1995;  26(8) 1471-1477
  CrossrefPubMedGoogle Scholar
• 57 Hart R G, Aguilar M I. Anticoagulation in atrial fibrillation: selected controversies including optimal anticoagulation intensity, treatment of intracerebral hemorrhage.  J Thromb Thrombolysis. 2008;  25(1) 26-32
  CrossrefPubMedGoogle Scholar
• 58 Levine M N, Raskob G, Beyth R J, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.  Chest. 2004;  126(3, suppl) 287S-310S
  CrossrefPubMedGoogle Scholar
• 59 Hylek E M, D'Antonio J, Evans-Molina C, Shea C, Henault L E, Regan S. Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation.  Stroke. 2006;  37(4) 1075-1080
  CrossrefPubMedGoogle Scholar
• 60 Fuster V, Rydén L E, Asinger R W American College of Cardiology et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology.  Eur Heart J. 2001;  22(20) 1852-1923
  CrossrefPubMedGoogle Scholar
• 61 Hart R G, Benavente O, Pearce L A. Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: a meta-analysis and hypothesis.  Cerebrovasc Dis. 1999;  9(4) 215-217
  CrossrefPubMedGoogle Scholar
• 62 Hart R G, Bhatt D L, Hacke W CHARISMA Investigators et al. Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial.  Cerebrovasc Dis. 2008;  25(4) 344-347
  CrossrefPubMedGoogle Scholar
• 63 Biblo L A, Yuan Z, Quan K J, Mackall J A, Rimm A A. Risk of stroke in patients with atrial flutter.  Am J Cardiol. 2001;  87(3) 346-349, A9
  CrossrefPubMedGoogle Scholar
• 64 Fang M C, Chang Y, Hylek E M et al.. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation.  Ann Intern Med. 2004;  141(10) 745-752
  CrossrefPubMedGoogle Scholar
• 65 Hylek E M, Skates S J, Sheehan M A, Singer D E. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation.  N Engl J Med. 1996;  335(8) 540-546
  CrossrefPubMedGoogle Scholar
• 66 Nieuwlaat R, Olsson S B, Lip G Y Euro Heart Survey Investigators et al. Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation.  Am Heart J. 2007;  153(6) 1006-1012
  CrossrefPubMedGoogle Scholar
• 67 Ang S Y, Peterson G M, Friesen W T, Vial J H. Review of antithrombotic drug usage in atrial fibrillation.  J Clin Pharm Ther. 1998;  23(2) 97-106
  CrossrefPubMedGoogle Scholar
• 68 Paciaroni M, Agnelli G, Caso V et al.. Atrial fibrillation in patients with first-ever stroke: frequency, antithrombotic treatment before the event and effect on clinical outcome.  J Thromb Haemost. 2005;  3(6) 1218-1223
  CrossrefPubMedGoogle Scholar
• 69 Ferro D, Loffredo L, Polimeni L, Violi F. Underuse of oral anticoagulants in patients with nonvalvular atrial fibrillation in Italy.  Intern Emerg Med. 2007;  2(1) 24-28
  CrossrefPubMedGoogle Scholar
• 70 Zehnder B S, Schaer B A, Jeker U, Cron T A, Osswald S. Atrial fibrillation: estimated excess rate of stroke due to lacking adherence to guidelines.  Swiss Med Wkly. 2006;  136(47–48) 757-760
  PubMedGoogle Scholar
• 71 Beyth R J, Antani M R, Covinsky K E et al.. Why isn't warfarin prescribed to patients with nonrheumatic atrial fibrillation?.  J Gen Intern Med. 1996;  11(12) 721-728
  CrossrefPubMedGoogle Scholar
• 72 Chang H J, Bell J R, Deroo D B, Kirk J W, Wasson J H. Physician variation in anticoagulating patients with atrial fibrillation. Dartmouth Primary Care COOP Project.  Arch Intern Med. 1990;  150(1) 83-86
  CrossrefPubMedGoogle Scholar
• 73 Partington S L, Abid S, Teo K, Oczkowski W, O'Donnell M J. Pre-admission warfarin use in patients with acute ischemic stroke and atrial fibrillation: the appropriate use and barriers to oral anticoagulant therapy.  Thromb Res. 2007;  120(5) 663-669
  CrossrefPubMedGoogle Scholar
• 74 Choudhry N K, Anderson G M, Laupacis A, Ross-Degnan D, Normand S L, Soumerai S B. Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis.  BMJ. 2006;  332(7534) 141-145
  CrossrefPubMedGoogle Scholar
• 75 Gattellari M, Worthington J, Zwar N, Middleton S. Barriers to the use of anticoagulation for nonvalvular atrial fibrillation: a representative survey of Australian family physicians.  Stroke. 2008;  39(1) 227-230
  PubMedGoogle Scholar
• 76 Dinh T, Nieuwlaat R, Tieleman R G et al.. Antithrombotic drug prescription in atrial fibrillation and its rationale among general practitioners, internists and cardiologists in The Netherlands—The EXAMINE-AF study. A questionnaire survey.  Int J Clin Pract. 2007;  61(1) 24-31
  CrossrefPubMedGoogle Scholar
• 77 Deplanque D, Leys D, Parnetti L SAFE II Investigators et al. Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study.  Br J Clin Pharmacol. 2004;  57(6) 798-806
  CrossrefPubMedGoogle Scholar
• 78 Hasenkamp J M, Sygehus S. Living with anticoagulants. Paper presented at: World Congress of Cardiology 2006 Barcelona, Spain;
  Google Scholar
• 79 Lip G Y, Golding D J, Nazir M, Beevers D G, Child D L, Fletcher R I. A survey of atrial fibrillation in general practice: the West Birmingham Atrial Fibrillation Project.  Br J Gen Pract. 1997;  47(418) 285-289
  PubMedGoogle Scholar
• 80 Kimmel S E, Chen Z, Price M et al.. The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study.  Arch Intern Med. 2007;  167(3) 229-235
  CrossrefPubMedGoogle Scholar
• 81 Nieuwlaat R, Capucci A, Lip G Y Euro Heart Survey Investigators et al. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation.  Eur Heart J. 2006;  27(24) 3018-3026
  CrossrefPubMedGoogle Scholar
• 82 Arnsten J H, Gelfand J M, Singer D E. Determinants of compliance with anticoagulation: a case-control study.  Am J Med. 1997;  103(1) 11-17
  CrossrefPubMedGoogle Scholar
• 83 Lane D A, Ponsford J, Shelley A, Sirpal A, Lip G Y. Patient knowledge and perceptions of atrial fibrillation and anticoagulant therapy: effects of an educational intervention programme. The West Birmingham Atrial Fibrillation Project.  Int J Cardiol. 2006;  110(3) 354-358
  CrossrefPubMedGoogle Scholar
• 84 Wofford J L, Wells M D, Singh S. Best strategies for patient education about anticoagulation with warfarin: a systematic review.  BMC Health Serv Res. 2008;  8 40
  CrossrefPubMedGoogle Scholar
• 85 Sawicki P T. Working Group for the Study of Patient Self-Management of Oral Anticoagulation . A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial.  JAMA. 1999;  281(2) 145-150
  CrossrefPubMedGoogle Scholar
• 86 Wilson F L, Racine E, Tekieli V, Williams B. Literacy, readability and cultural barriers: critical factors to consider when educating older African Americans about anticoagulation therapy.  J Clin Nurs. 2003;  12(2) 275-282
  CrossrefPubMedGoogle Scholar
• 87 Reynolds M W, Fahrbach K, Hauch O et al.. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis.  Chest. 2004;  126(6) 1938-1945
  CrossrefPubMedGoogle Scholar
• 88 Stroke Prevention in Atrial Fibrillation Study. Final results.  Circulation. 1991;  84(2) 527-539
  CrossrefPubMedGoogle Scholar
• 89 The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators . The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation.  N Engl J Med. 1990;  323(22) 1505-1511
  CrossrefPubMedGoogle Scholar
• 90 Connolly S J, Laupacis A, Gent M, Roberts R S, Cairns J A, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study.  J Am Coll Cardiol. 1991;  18(2) 349-355
  CrossrefPubMedGoogle Scholar
• 91 Ezekowitz M D, Bridgers S L, James K E Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation.  N Engl J Med. 1992;  327(20) 1406-1412
  CrossrefPubMedGoogle Scholar
• 92 Hirsh J, Dalen J E, Deykin D, Poller L. Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range.  Chest. 1992;  102(4, suppl) 312S-326S
  PubMedGoogle Scholar
• 93 Bajpai A, Savelieva I, Camm A J. Epidemiology and economic burden of atrial fibrillation.  US Cardiovasc Dis. 2007;  1 14-17
  PubMedGoogle Scholar
• 94 Wattigney W A, Mensah G A, Croft J B. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention.  Circulation. 2003;  108(6) 711-716
  CrossrefPubMedGoogle Scholar
• 95 Stewart S, Murphy N F, Murphy N, Walker A, McGuire A, McMurray J J. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK.  Heart. 2004;  90(3) 286-292
  CrossrefPubMedGoogle Scholar
• 96 Le Heuzey J Y, Paziaud O, Piot O et al.. Cost of care distribution in atrial fibrillation patients: the COCAF study.  Am Heart J. 2004;  147(1) 121-126
  CrossrefPubMedGoogle Scholar
• 97 Coyne K S, Paramore C, Grandy S, Mercader M, Reynolds M, Zimetbaum P. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States.  Value Health. 2006;  9(5) 348-356
  CrossrefPubMedGoogle Scholar
• 98 Szucs T D, Bramkamp M. Pharmacoeconomics of anticoagulation therapy for stroke prevention in atrial fibrillation: a review.  J Thromb Haemost. 2006;  4(6) 1180-1185
  CrossrefPubMedGoogle Scholar
• 99 Jones M, McEwan P, Morgan C L, Peters J R, Goodfellow J, Currie C J. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population.  Heart. 2005;  91(4) 472-477
  CrossrefPubMedGoogle Scholar
• 100 Regier D A, Sunderji R, Lynd L D, Gin K, Marra C A. Cost-effectiveness of self-managed versus physician-managed oral anticoagulation therapy.  CMAJ. 2006;  174(13) 1847-1852
  PubMedGoogle Scholar
• 101 Caro J J. An economic model of stroke in atrial fibrillation: the cost of suboptimal oral anticoagulation.  Am J Manag Care. 2004;  10(14, suppl) S451-S458 discussion S458-S461
  PubMedGoogle Scholar
• 102 van Geest-Daalderop J H, Hutten B A, Péquériaux N C, Haas F J, Levi M, Sturk A. The influence on INRs and coagulation factors of the time span between blood sample collection and intake of phenprocoumon or acenocoumarol: consequences for the assessment of the dose.  Thromb Haemost. 2007;  98(4) 738-746
  PubMedGoogle Scholar
• 103 Phillips K W, Ansell J. Outpatient management of oral vitamin K antagonist therapy: defining and measuring high-quality management.  Expert Rev Cardiovasc Ther. 2008;  6(1) 57-70
  CrossrefPubMedGoogle Scholar
• 104 Bernardo A, Völler H.. Arbeitsgemeinschaft Selbstkontrolle der Antikoagulation (ASA) [Guidelines for “coagulation self-management”].  Dtsch Med Wochenschr. 2001;  126(12) 346-351
  Article in Thieme ConnectPubMedGoogle Scholar
• 105 Ansell J, Jacobson A, Levy J, Völler H, Hasenkam J M. International Self-Monitoring Association for Oral Anticoagulation . Guidelines for implementation of patient self-testing and patient self-management of oral anticoagulation. International consensus guidelines prepared by International Self-Monitoring Association for Oral Anticoagulation.  Int J Cardiol. 2005;  99(1) 37-45
  CrossrefPubMedGoogle Scholar
• 106 Fihn S D, McDonell M B, Vermes D National Consortium of Anticoagulation Clinics et al. A computerized intervention to improve timing of outpatient follow-up: a multicenter randomized trial in patients treated with warfarin.  J Gen Intern Med. 1994;  9(3) 131-139
  CrossrefPubMedGoogle Scholar
• 107 Fitzmaurice D A, Hobbs F D, Delaney B C, Wilson S, McManus R. Review of computerized decision support systems for oral anticoagulation management.  Br J Haematol. 1998;  102(4) 907-909
  CrossrefPubMedGoogle Scholar
• 108 Fitzmaurice D A, Hobbs F D, Murray E T, Holder R L, Allan T F, Rose P E. Oral anticoagulation management in primary care with the use of computerized decision support and near-patient testing: a randomized, controlled trial.  Arch Intern Med. 2000;  160(15) 2343-2348
  CrossrefPubMedGoogle Scholar
• 109 Manotti C, Moia M, Palareti G, Pengo V, Ria L, Dettori A G. Effect of computer-aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated PRogram for Oral Anticoagulant Treatment).  Haematologica. 2001;  86(10) 1060-1070
  PubMedGoogle Scholar
• 110 Ansell J E. Optimizing the efficacy and safety of oral anticoagulant therapy: high-quality dose management, anticoagulation clinics, and patient self-management.  Semin Vasc Med. 2003;  3(3) 261-270
  Article in Thieme ConnectPubMedGoogle Scholar
• 111 Ansell J, Hollowell J, Pengo V, Martinez-Brotons F, Caro J, Drouet L. Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM).  J Thromb Thrombolysis. 2007;  23(2) 83-91
  CrossrefPubMedGoogle Scholar
• 112 Nichol M B, Knight T K, Dow T et al.. Quality of anticoagulation monitoring in nonvalvular atrial fibrillation patients: comparison of anticoagulation clinic versus usual care.  Ann Pharmacother. 2008;  42(1) 62-70
  PubMedGoogle Scholar
• 113 Cromheecke M E, Levi M, Colly L P et al.. Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison.  Lancet. 2000;  356(9224) 97-102
  CrossrefPubMedGoogle Scholar
• 114 Völler H, Glatz J, Taborski U, Bernardo A, Dovifat C, Heidinger K. Self-management of oral anticoagulation in nonvalvular atrial fibrillation (SMAAF study).  Z Kardiol. 2005;  94(3) 182-186
  CrossrefPubMedGoogle Scholar
• 115 Heneghan C, Alonso-Coello P, Garcia-Alamino J M, Perera R, Meats E, Glasziou P. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis.  Lancet. 2006;  367(9508) 404-411
  CrossrefPubMedGoogle Scholar
• 116 Menéndez-Jándula B, Souto J C, Oliver A et al.. Comparing self-management of oral anticoagulant therapy with clinic management: a randomized trial.  Ann Intern Med. 2005;  142(1) 1-10
  PubMedGoogle Scholar
• 117 Matchar D B, Jacobson A K, Edson R G et al.. The impact of patient self-testing of prothrombin time for managing anticoagulation: rationale and design of VA Cooperative Study #481—the Home INR Study (THINRS).  J Thromb Thrombolysis. 2005;  19(3) 163-172
  CrossrefPubMedGoogle Scholar

Marcel LeviM.D. 

Department Internal Medicine, Academic Medical Centre F-4

Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands

Email: m.m.levi@amc.uva.nl